Three-Component MMF Prodrug for Reduced GI Side Effects and Flushing
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing dimethyl fumarate treatments for conditions like psoriasis and multiple sclerosis suffer from severe side effects such as gastrointestinal disorders and flushing, which are not adequately addressed by current precursor drugs like diroximel fumarate.
Innovation Solution
A novel three-component prodrug compound, represented by Chemical Formula 1, comprising monomethyl fumarate linked with 2-acetoxybenzoic acid through 4-hydroxybenzyl alcohol, which is metabolized to MMF, HBA, and salicylic acid, offering improved pharmacokinetics and reduced side effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If dimethyl fumarate is used to treat psoriasis and multiple sclerosis, then therapeutic efficacy is achieved, but severe side effects such as gastrointestinal disorders and flushing occur
Solution Approach 1:
The dimethyl fumarate molecule is segmented into two components: monomethyl fumarate (the active therapeutic agent) and salicylic acid (the side effect mitigator). This segmentation allows the therapeutic effects to be preserved while the harmful side effects are reduced, as salicylic acid counteracts gastrointestinal irritation and flushing without interfering with the immunomodulatory and antioxidant actions of monomethyl fumarate
Solution Approach 2:
Salicylic acid acts as an intermediary substance that mediates between the therapeutic action of monomethyl fumarate and the body's tolerance to side effects. It specifically counteracts the harmful effects (gastrointestinal disorders and flushing) while allowing the beneficial therapeutic effects to proceed, effectively serving as a protective mediator
2Object-affected harmful factors
If precursor drugs like diroximel fumarate are used to reduce side effects, then gastrointestinal tolerance improves, but flushing side effects remain inadequately addressed
Solution Approach 1:
The compound of formula 1 provides universal side effect management by simultaneously addressing multiple types of adverse reactions (both gastrointestinal disorders and flushing) through the dual-component design. Monomethyl fumarate provides therapeutic efficacy while salicylic acid provides broad-spectrum protection against various side effects, making the formulation universally applicable for improving tolerability across different patient responses
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The compound exhibits enhanced bioavailability, pharmacokinetics, and reduced side effects, effectively treating or improving immune system disorders and inflammatory diseases while maintaining therapeutic efficacy.
Implementation Method 1
The compound of formula 1 is metabolized by esterases in the body to produce MMF (monomethyl fumarate), HBA (4-hydroxybenzyl alcohol), and 2-acetoxybenzoic acid, respectively. In addition, 2-acetoxybenzoic acid (aspirin) is also metabolized by esterases in the body to salicylic acid and acetic acid.
Implementation Method 2
The compound of formula 1 is metabolized by esterases in the body to produce MMF (monomethyl fumarate), HBA (4-hydroxybenzyl alcohol), and 2-acetoxybenzoic acid, respectively.
Data Source
AI summary
The present disclosure relates to a novel compound that allows for the production of monomethyl fumarate after being administered, a pharmaceutical composition containing same as an active ingredient, and a medicinal use thereof.